A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Sponsored by Tallac Therapeutics
About this trial
Last updated 2 years ago
Study ID
INCLINE-101
Status
Recruiting
Type
Interventional
Phase
Phase 1/Phase 2
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 3 years ago
What is this trial about?
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety,
pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered
intravenously.
What are the participation requirements?
Inclusion Criteria
1. Histologically or cytologically-documented solid tumors.
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
3. Demonstrate adequate organ function.
Exclusion Criteria
1. Prior history of or active malignant disease other than that being treated in this study.
2. Known brain metastases or cranial epidural disease.
3. A known hypersensitivity to the components of the study therapy or its' analogs.